Sobaps S.A Pharmaceutical Import Profile — Benin (DGFT 2022–2026)

Name: Sobaps S.A Pharmaceutical Import Records from India — 2 Products, $700.0K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Sobaps S.A — Pharmaceutical Importer Profile (2026) | 2 Products, $700.0K Trade | TransData Nexus

Sobaps S.A

Pharmaceutical Importer · Benin · Antimalarial & Antiparasitic Focus · $700.0K Total Trade · DGFT Verified

Sobaps S.A is a pharmaceutical importer based in Benin with a total trade value of $700.0K across 2 products in 2 therapeutic categories. Based on 14 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Sobaps S.A sources from 9 verified Indian suppliers, with Sidhaant Life Sciences Private Limited accounting for 76.5% of imports.

Sobaps S.A — Import Portfolio & Supplier Network

Sobaps S.A import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Sobaps S.A?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Sidhaant Life Sciences Private Limited	$2.7M	88	76.5%
Unijules Life Sciences Limited	$303.9K	12	8.7%
Swiss Parenterals Limited	$146.6K	8

What Formulations Does Sobaps S.A Import?

Formulation	Value	Ships
Erythromycin stearate tablets BP 250 MG	$200.0K	4
.. povidone iodine solution BP 10%	$200.0K	4
Amoxicillin for oral suspension USP	$199.4K	7
Iohexo-m 350 (iohexol injection USP	$158.4K	4
Albendazole oral suspension 400MG/10ML	$155.1K	4
Quinine sulfate tablet BP 300 MG,bt#eht23037 to eht23046,mfg#12/2023,exp#11/2026(tax inv#hr/si/2324/0055 dt. 12.01.2024	$150.0K	3
Quinine sulfate tablet BP 100 MG,bt#eht23011 to eht23022,mfg#12/2023,exp#11/2026(tax inv#hr/si/2324/0053 dt. 11.01.2024	$150.0K	3
Quinine sulfate tablets BP 300 MG (mfg.by : medicamen biotech ltd. gst # 05aaacm1217a1zf) (qty:6324400 units	$150.0K	3
Ferrous fumarate tablets BP 200MG, bt#eft24029 to eft24033, mfg#02/2024, exp#01/2026, bt#eft24074 to eft24093	$103.7K	3
Ferric ammonium citrate, folic acid &	$100.0K	2
Erythromycin stearate TAB BP 250MG bt te2212358 mfg 12 2022 exp 11 2024 bt te2301005 te2301006 mfg 01 2023 exp 12	$100.0K	2
Ferric ammonium citrate folic acid vitamin b12 syrup bt mel23006 mfg 01 2023 exp 12 2024 bt mel23017 to	$92.1K	2
Amoxicillin oral suspension BP 250 MG	$50.0K	1
Hyoscine butylbromide INJ BP 1 ML	$50.0K	1
Ferric ammmonium citrate,folic acid &	$50.0K	1

Sobaps S.A imports 116 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Quinine	Antimalarial & Antiparasitic	$450.0K	9	2.3%	4
2	Erythromycin	Antibiotics	$250.0K	5	0.3%	10

Sobaps S.A imports 2 pharmaceutical products across 2 categories into Benin totaling $700.0K.

Sobaps S.A — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Sobaps S.A, officially known as the Société Béninoise pour l’Approvisionnement en Produits de Santé, is a state-owned enterprise established by decree n°2020-324 on June 24, 2020, and commenced operations on September 4, 2020. As the sole shareholder, the government of Benin has entrusted Sobaps S.A with the critical mission of ensuring the supply, storage, and wholesale distribution of essential health products across the nation. This initiative is part of a broader reform aimed at enhancing the efficiency and accessibility of healthcare services in Benin. (sobaps.bj)

Headquartered in the Enagnon-Akpakpa district of Cotonou, Sobaps S.A operates with a capital of 11,872,380,000 FCFA. The company is structured to serve both public and private healthcare facilities, including hospitals, clinics, and pharmacies, by providing a range of products such as generic medicines, medical devices, laboratory reagents, and essential health commodities. Through its operations, Sobaps S.A plays a pivotal role in maintaining the availability of quality health products at affordable prices, thereby contributing significantly to the improvement of public health standards in Benin. (sobaps.bj)

2Distribution Network

Sobaps S.A has strategically established a robust distribution network to effectively serve the diverse healthcare needs across Benin. The central hub is located at the Ministry of Health's premises in Cotonou, which accounts for approximately 75% of the company's sales. This central agency is equipped with five main warehouses dedicated to storing a wide array of health products, including medicines, medical consumables, diagnostic reagents, and veterinary products. Additionally, the facility features cold storage rooms to accommodate temperature-sensitive items. (sobaps.bj)

To ensure comprehensive national coverage, Sobaps S.A operates two regional agencies: one in Parakou, near the Parakou Health Center, and another in Natitingou, within the premises of the Atacora Departmental Health Directorate. These regional offices are equipped with storage facilities and are staffed by dedicated personnel to manage the distribution of health products to public and private healthcare institutions in their respective regions. This decentralized approach enables Sobaps S.A to efficiently meet the healthcare demands of both urban and rural populations across Benin. (sobaps.bj)

3Industry Role

Sobaps S.A serves as the primary wholesaler and central procurement agency for health products in Benin. By managing the supply chain from procurement to distribution, the company ensures that essential medicines and medical supplies are consistently available to healthcare providers nationwide. This centralized approach allows Sobaps S.A to negotiate better pricing, maintain quality control, and streamline logistics, thereby enhancing the overall efficiency of the pharmaceutical supply chain in the country. While Sobaps S.A is not a parallel importer or a hospital supplier, its role as a wholesaler is crucial in supporting the operations of hospitals, clinics, and pharmacies by providing them with a reliable source of health products. (sobaps.bj)

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Sobaps S.A

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Sobaps S.A's sourcing strategy reveals a significant concentration in its supplier base, particularly from India. The company has imported a total of $700,000 USD worth of finished pharmaceutical formulations from India across 14 shipments, indicating a focused procurement approach. The top five products imported include Quinine ($450,000 USD) and Erythromycin ($250,000 USD), which together constitute 100% of the company's pharmaceutical imports from India. This high level of concentration suggests a strategic choice to streamline procurement processes and possibly leverage favorable pricing or quality from these specific suppliers.

However, this concentrated sourcing model also presents potential risks. Dependence on a limited number of suppliers can lead to vulnerabilities in the supply chain, especially if there are disruptions such as production delays, regulatory changes, or geopolitical issues affecting the supplier's country. The shipment data indicates a stable relationship with these Indian suppliers, as evidenced by the consistent number of shipments over the period. Nonetheless, Sobaps S.A may consider diversifying its supplier base to mitigate potential risks associated with over-reliance on a few suppliers.

2Supply Chain Resilience

Sobaps S.A's supply chain resilience is closely tied to its sourcing strategy from India. The company's reliance on a select group of Indian suppliers for its pharmaceutical imports necessitates a thorough assessment of these suppliers' operational stability and compliance with international standards. The shipment data indicates a consistent flow of products, suggesting a reliable supply chain; however, the lack of information on backup suppliers and the diversity of formulations imported raises concerns about the company's preparedness for potential supply chain disruptions.

Importing Pharmaceuticals into Benin — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Benin

1Regulatory Authority & Framework

In Benin, the regulatory authority responsible for the oversight and registration of pharmaceutical products is the Agence Béninoise de Régulation et d'Enregistrement des Produits (ABREP). ABREP is tasked with ensuring that all pharmaceutical drugs manufactured, imported, exported, advertised, sold, distributed, or used within the country comply with established regulations and standards. This includes the registration of imported pharmaceutical drugs, which must be conducted in accordance with ABREP's guidelines and the provisions of the relevant legislation.

The registration process involves the submission of necessary documentation, which can be facilitated by an ABREP-accredited legal agent. This process ensures that imported pharmaceutical products meet the required safety, efficacy, and quality standards before they are permitted for use in Benin. By adhering to these regulatory frameworks, Sobaps S.A and other stakeholders in the pharmaceutical supply chain contribute to the protection of public health and the integrity of the healthcare system in Benin.

2Import Licensing & GMP

Import licensing in Benin is governed by the regulations set forth by ABREP. All pharmaceutical products intended for importation must undergo a registration process to ensure compliance with national standards. This process includes the submission of necessary documentation, which can be facilitated by an ABREP-accredited legal agent. The registration ensures that imported pharmaceutical products meet the required safety, efficacy, and quality standards before they are permitted for use in Benin.

Sobaps S.A — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Sobaps S.A's focus on importing antimalarial and antibiotic products aligns with the prevalent health challenges in Benin.

TransData Nexus Research · DGFT trade data analysisMar 2026

Frequently Asked Questions — Sobaps S.A

What products does Sobaps S.A import from India?

Sobaps S.A imports 2 pharmaceutical products across 2 categories. Top imports: Quinine ($450.0K), Erythromycin ($250.0K).

Who supplies pharmaceuticals to Sobaps S.A from India?

Sobaps S.A sources from 9 verified Indian suppliers. The primary supplier is Sidhaant Life Sciences Private Limited (76.5% of imports, $2.7M).

What is Sobaps S.A's total pharmaceutical import value?

Sobaps S.A's total pharmaceutical import value from India is $700.0K, based on 14 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Sobaps S.A focus on?

Sobaps S.A imports across 2 categories. The largest: Antimalarial & Antiparasitic (64.3%), Antibiotics (35.7%).

Get Full Sobaps S.A Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.